Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
DNAtrix and Merck & Co. Inc. (NYSE:MRK, Kenilworth, N.J.) began the open-label, U.S. Phase II CAPTIVE/KEYNOTE-192 trial to evaluate a single intratumoral injection of DNX-2401 followed 7-9 days later...